Even so, based on KEYNOTE-189, carboplatin/pemetrexed/pembrolizumab obtained approval from the FDA in 2018 as first-line therapy for advanced NSCLC without EGFR/ALK alterations [37]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.